Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published on August 19
Plasma-derived therapies treat rare diseases and critical conditions, creating consistent demand that's largely recession-proof. When a market leader reports 14% profit growth, it signals strength across the entire ecosystem.
These specialised biologics command premium prices due to their life-saving nature and high barriers to entry. Companies in this space often enjoy strong margins and pricing flexibility that traditional pharmaceuticals can't match.
From plasma collection technology to advanced bioprocessing, this sector is ripe with innovation opportunities. Early investors in the right companies could benefit as new therapies and technologies reach the market.
CSL's impressive 14% profit surge, driven by its plasma division, signals strong fundamentals across the plasma-derived therapies market. This specialised biologics sector offers resilient demand and significant pricing power, making it an attractive investment theme for those seeking targeted healthcare exposure.
This group focuses on the expanding plasma therapies ecosystem, from blood plasma collection to bioprocessing technologies and final medicine development. These companies operate in a specialised market with high barriers to entry and consistent demand for life-saving treatments.
Each company was handpicked by professional analysts for their role in the plasma profit pipeline. From established market leaders to innovative suppliers supporting the bioprocessing chain, these stocks represent various opportunities within this growing healthcare segment.
Summary and investor takeaways for the provided basket market capitalisation data.
GRFS: $8.16B
HAE: $2.47B
RGEN: $8.82B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+6
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 455.45% over the next year.
14 of 16 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+455.45%
